Blue Square Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Blue Square Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,769	Closed	-$563K	–	80
2019 Q4	$563K	Buy	3,769 +1,870	+98%	+$254K	0.44%	61
2019 Q3	$243K	Buy	+1,899	New	+$255K	0.19%	67

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Blue Square Asset Management's JAZZ Position: Q1 2020 in Review

Blue Square Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 3,769 shares — an estimated $563K sold.

Blue Square Asset Management first reported a position in JAZZ in Q3 2019 and held it in 2 quarters. The position peaked at $563K in Q4 2019. 407 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

Blue Square Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Blue Square Asset Management sold 3,769 Jazz Pharmaceuticals shares in Q1 2020, an estimated $563K.
Blue Square Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2019 and held it in 2 quarters.
Blue Square Asset Management's Jazz Pharmaceuticals position peaked at $563K in Q4 2019.
407 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Blue Square Asset Management's 13F filing for Q1 2020, filed 28 Apr 2020.